Exact Sciences (EXAS) Tops Q2 EPS by 12c, Updates Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. DECK
2. RNG
3. WDC
4. BMY
5. BYD
6. WCN
7. SPOT
8. SPY
9. FIX
10. NDAQ

Go back to Exact Sciences (EXAS) Tops Q2 EPS by 12c, Updates Guidance

Exact Sciences Announces Second Quarter 2025 Results

August 6, 2025 4:05 PM EDT

Reports record revenue, improves adjusted EBITDA, raises full-year guidance

Second quarter and recent highlights

Delivered record total second quarter revenue of $811 million, an increase of 16% on a reported and core revenue basis, including Screening revenue of $628 million and Precision Oncology revenue of $183 million Raised full-year 2025 revenue and adjusted EBITDA guidance midpoints by $55 million and $25 million, respectively Entered into an exclusive license agreement with Freenome for blood-based colorectal cancer screening tests Gained Medicare coverage for Oncodetect molecular residual disease and recurrence monitoring test Announced a multi-year... More